PGX vs XBI
Invesco Preferred ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.50% for PGX.
- • PGX pays a higher dividend yield (6.16%).
Side-by-side metrics
| Metric | PGX | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.35% |
Dividend yield Trailing 12-month yield. | 6.16% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $3.92B | $8.30B |
YTD return | 1.46% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.22 | 1.09 |
P/E ratio | — | — |
Last price | $11.16 | $133.66 |
Inception | — | — |
Issuer | Invesco | State Street |
PGX top holdings
| JPMPC | JPMorgan Chase & Co 6% PRF PERPETUAL USD 25 - Dep rep 1/400 Ser EE | 1.75% |
| JPMPD | JPMorgan Chase & Co Pfd | 1.57% |
| WFCPZ | Wells Fargo & Co 4.75% PRF PERPETUAL USD 25 Series Z Class A | 1.43% |
| JPMPL | JPMorgan Chase & Co PRF PERPETUAL USD - Ser LL 1/400th Int | 1.35% |
| JPMPM | JPMorgan Chase & Co PRF PERPETUAL USD - Ser MM 1/400th | 1.35% |
| BACPB | Bank of America Corp 6% PRF PERPETUAL USD 25 - Ser GG 1/1000th int | 1.28% |
| TPC | AT&T Inc 4.75% PRF PERPETUAL USD 25 - 1/1000th Int Ser C | 1.23% |
| BACPM | Bank of America Corp Pfd | 1.14% |
| JPMPK | JPMorgan Chase & Co PRF PERPETUAL USD 25 - Ser JJ 1/400 int | 1.07% |
| COFPI | Capital One Financial Corp Series I | 1.06% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About PGX
PGX (Invesco Preferred ETF) is US investment-grade preferred stocks. Managed by Invesco, the fund carries $3.9B in assets under management, an expense ratio of 0.50%, a dividend yield of 6.16%. Its largest holding is JPMorgan Chase & Co 6% PRF PERPETUAL USD 25 - Dep rep 1/400 Ser EE (JPMPC), which represents 1.8% of the portfolio. Utilities is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.